Lazcluze

Lazertinib, the active ingredient in Lazcluze, is a tyrosine kinase inhibitor presented as a unknown/unknown for oral use. It treats non‑small cell lung cancer that carries epidermal growth factor receptor (EGFR) mutations in adult patients.

GNH USA supplies Lazcluze as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

Lazcluze is a targeted therapy that acts on EGFR‑mutated non‑small cell lung cancer.

Non‑small cell lung cancer with EGFR mutations: improves progression‑free survival and tumor response in patients whose tumours harbor activating EGFR alterations.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Diarrhea: mild to moderate gastrointestinal upset. - Skin rash: papulopustular eruption, often on the face or trunk. - Nausea: occasional feeling of queasiness. - Decreased appetite: reduced food intake. - Fatigue: general tiredness. - Elevated liver enzymes: transient increase in ALT/AST.

Serious or Rare Side Effects: - Interstitial lung disease: new or worsening respiratory symptoms. - Severe hepatic injury: marked elevation of liver enzymes or jaundice. - QT interval prolongation: potential cardiac arrhythmia risk. - Stevens‑Johnson syndrome: severe skin and mucosal reactions. - Grade 3/4 neutropenia: significant reduction in white blood cells. - Hepatotoxicity: liver failure requiring medical intervention.

Patients should be monitored for specific safety concerns before and during treatment.

Liver function monitoring: assess ALT, AST, and bilirubin regularly. Cardiac assessment: obtain baseline ECG and monitor QT interval. Pulmonary evaluation: watch for signs of interstitial lung disease. Avoid use in severe hepatic impairment: contraindicated in patients with Child‑Pugh C. Drug interaction awareness: review concomitant medications that affect CYP3A4. Store at below 25°C: keep in original container, protect from moisture and light.

Lazcluze may interact with other medicines that influence its metabolism or cardiac safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase plasma concentrations. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy. - QT‑prolonging agents (e.g., certain antiarrhythmics): additive risk of arrhythmia.

Moderate Interactions (Monitor Closely):\n- Antacids containing aluminum or magnesium: may affect absorption, separate dosing by at least 2 hours. - Moderate CYP3A4 inhibitors (e.g., erythromycin): may modestly raise drug levels. - Warfarin: monitor INR as EGFR inhibitors can alter coagulation parameters.